---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031410"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:05:47.765706+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q3 revenue $1.0M (down 52% QoQ), net loss $9.3M; engages Perella Weinburg for strategic alternatives

## Summary
- Total revenue $1.0M in Q3 2022 vs $2.1M prior quarter; net loss $9.3M ($0.08 per share) vs $13.8M loss ($0.15) in prior year.
- DetermaRx sample volume up 51% YoY; onboards physician base +62% YoY.
- Engaged Perella Weinburg Partners as advisor to evaluate strategic alternatives.
- Cash, equivalents, and marketable securities $34.2M as of Sept 30, 2022.
- DetermaIO sample volume from Early Adopters grew 117% QoQ.

## SEC filing metadata
- accession: 0001493152-22-031410
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/0001493152-22-031410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031410
- JSON: https://secwatch.observer/filing/0001493152-22-031410.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031410.txt

## Key facts
- Earnings Releases
  Insight Molecular Diagnostics Inc. reported the three and nine months ended September 30, 2022 results: revenue $1.0 million, net income $9.3 million, EPS $0.08.
  - Period: the three and nine months ended September 30, 2022
  - Revenue: $1.0 million
  - Net income: $9.3 million
  - EPS: $0.08
  - Result: reported results
  source text: from the past few years transition to market launches of several new high-value, reimbursed tests over coming quarters.” Third Quarter 2022 Financial Results Total revenue was $1.0 million for the third quarter of 2022, compared to $2.1 million for the prior quarter. Third quarter revenues associated with DetermaRx were $1.0 million, an increase of $0.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315222031410/0001493152-22-031410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.